October 20, 2010
Asahi Kasei Pharma Corp.

Application for approval to manufacture and sell MN-10-T osteoporosis drug in Japan
Asahi Kasei Pharma today filed an application for approval to manufacture and sell MN-10-T (teriparatide acetate) as an osteoporosis drug in Japan.
About MN-10-T
Generic name: Teriparatide acetate
Product name: Teribone™ for subcutaneous injection (tentative)
Indication: Osteoporosis with high risk of fracture (tentative)
Characteristics: Teriparatide acetate is a human parathyroid hormone preparation that facilitates bone formation. It has been verified that weekly subcutaneous injections of teriparatide acetate effectively inhibit new vertebral fracture.*
The efficacy in inhibiting fracture is obtained by increasing bone strength with both improved bone quality and increased bone density.
  * Compression fracture of the centrum of vertebra (cylindrical part of the bones of the spine) due to brittleness caused by osteoporosis.
About osteoporosis
  It is estimated that more than 10 million people suffer from osteoporosis in Japan, including those not receiving treatment,* and the number is increasing as the population ages. Since osteoporosis carries an increased risk of vertebral and femoral neck fracture, with a high probability of resulting in confinement to bed, the implementation of effective measures against osteoporosis is an important social issue.

Asahi Kasei Pharma believes that, with its efficacy in inhibiting fracture, this drug will make a significant contribution to the treatment of osteoporosis.
  * Satoshi Soen, et al., Progress in Medicine, Vol. 27, No. 3, 621-627, 2007.
Click here for PDF


Adobe Readeris required to view these PDF files.

page top